TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$22.83 USD
+0.65 (2.93%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $22.82 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.83 USD
+0.65 (2.93%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $22.82 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
Why These Pharma ETFs Rallied on Thursday
by Sanghamitra Saha
A few pharma ETFs hit a one-month high on Feb 28. Why?
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
by Zacks Equity Research
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
by Zacks Equity Research
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
TG Therapeutics (TGTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TGTX) Outperforming Other Medical Stocks This Year?
Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher
by Zacks Equity Research
Canopy Growth (CGC) shares rose more than 11% in the last trading session, amid huge volumes.
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
What's in Store for GW Pharma (GWPH) This Earnings Season?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.82% and -5.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate TG Therapeutics (TGTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
TG Therapeutics (TGTX) shares rose nearly 9% in the last trading session, amid huge volumes.
Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
by Zacks Equity Research
Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options
by Zacks Equity Research
Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?
by Zacks Equity Research
Investors in TG Therapeutics, Inc. (TGTX) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
by Zacks Equity Research
Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock which has high level of implied volatility
5 Top Performing Stocks of the Best ETF of Q1
by Sweta Killa
Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.
How to Uncover Institutional Buying
by Kevin Matras
Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include COLM, NXTM, OCR, OVAS and TGTX.